Latest SNOMED concepts for COVID-19 within FDB Multilex

The Multilex data files have been updated to accommodate the recent tranche of new SNOMED codes to support the testing regimen for COVID-19
FDB today announced that its Multilex data files have been updated to accommodate the most recent tranche of new SNOMED codes to support the testing regimen for COVID-19. This means that FDB can help vendors and end users to support the effective management of cases in the UK.
 
 
 
FDB included the new April 22nd SNOMED codes, largely concerned with testing, into its May data cut and the company will continue to include further incremental 'micro-releases' from UK SNOMED CT. The next micro-release will be made available from NHS Digital on May 20th and will include concepts related to exposure to the virus and more concepts to represent test results.  FDB will continue to fast-track these frequent updates into monthly releases.
 
 
 
Ian Arrowsmith, Head of Clinical Content Operations at FDB says: ‘The next releases of UK SNOMED CT Drug extension will be on 20 May and 17 June, and we will be fast-tracking this content into our monthly releases, so that we can make this data available to our customers as soon as possible.’
 
 
 
SNOMED CT is a structured clinical vocabulary for use in an electronic health record and provides comprehensive and precise clinical health terminology.
 
 
 
If you would like to learn more about Multilex, please click here.
 
 
 
For further information, please contact suzie@castlegatecommunications.co.uk or call 0772 999 3721.
 
 
 
About First Databank (FDB)
FDB is the UK’s leading supplier of clinical decision support and drug knowledge. Its solutions are integrated into healthcare systems across a wide range of settings, enabling evidence-based prescribing by providing essential checks to support clinicians. Its in-house team of expert clinicians check multiple sources and interpret NICE and other best practice resources to ensure that all medicines’ information is up to date. Its position within the market means that FDB adopts new industry standards quickly and easily, while its clinical decision support can be fine-tuned to meet the needs of specialised environments to enhance clinical care, patient safety and quality.